# Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

> **NCT03387163** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 402 (actual)

## Conditions studied

- Heart Failure, Systolic

## Interventions

- **DRUG:** Sacubitril/Valsartan

## Key facts

- **NCT ID:** NCT03387163
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-09
- **Primary completion:** 2019-06-21
- **Final completion:** 2019-06-21
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2019-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03387163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03387163, "Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03387163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*